Expert Consensus
International Consensus on Severe Lung Cancer—The Second Edition
Translational Lung Cancer Research
2026;
15
(4)
:69
.
(30 April 2026)
Original Article
Deep learning model based on automated CT image segmentation for predicting the optimal radiotherapy protocol in limited-stage small cell lung cancer patients: a multicenter study
Translational Lung Cancer Research
2026;
15
(4)
:70
.
(30 April 2026)
Association of PD-L1 expression and clinical outcomes in ROS1-rearranged advanced non-small cell lung cancer treated with entrectinib
Translational Lung Cancer Research
2026;
15
(4)
:71
.
(30 April 2026)
DNA hypomethylation-activated PRAME drives early-stage lung adenocarcinoma recurrence via ZNF740 and PI3K/AKT/mTOR signaling
Translational Lung Cancer Research
2026;
15
(4)
:72
.
(30 April 2026)
Predictors of radiation pneumonitis after postoperative radiotherapy in completely resected pathologic stage III-N2 non-small cell lung cancer: a secondary analysis of a prospective cohort
Translational Lung Cancer Research
2026;
15
(4)
:73
.
(30 April 2026)
Perioperative anxiety and depression predict long-term survival after neoadjuvant therapy in non-small cell lung cancer: a multicenter analysis
Translational Lung Cancer Research
2026;
15
(4)
:74
.
(30 April 2026)
TLR7 induces autophagy in non-small cell lung cancer tumor cells and influences anti-tumors responses in patients
Translational Lung Cancer Research
2026;
15
(4)
:75
.
(30 April 2026)
Prognostic nomogram for extensive-stage small-cell lung cancer in the immunotherapy era: a multicenter study of first-line platinum-etoposide with or without a PD-1/PD-L1 inhibitor
Translational Lung Cancer Research
2026;
15
(4)
:76
.
(30 April 2026)
LUADnet: a deep learning model for prediction of clinical outcomes in lung adenocarcinoma based on gene expression signatures
Translational Lung Cancer Research
2026;
15
(4)
:77
.
(30 April 2026)
Perioperative inflammation, anesthesia modulation and cellular signaling in lung cancer: an integrated transcriptomic and single- cell analysis
Translational Lung Cancer Research
2026;
15
(4)
:78
.
(30 April 2026)
Mid-term efficacy and safety of transbronchial cryoablation for stage IA peripheral lung cancer: a retrospective analysis
Translational Lung Cancer Research
2026;
15
(4)
:79
.
(30 April 2026)
Preoperative 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT)-based strategy for predicting negative mediastinal lymph node metastasis status in non-small cell lung cancer
Translational Lung Cancer Research
2026;
15
(4)
:80
.
(30 April 2026)
Distinct mutation landscape with similar immune microenvironment in primary simultaneous operable squamous cell carcinoma and peripheral-type small-cell lung cancer
Translational Lung Cancer Research
2026;
15
(4)
:81
.
(30 April 2026)
Impact of effective dose to immune cells (EDIC) on survival in limited-stage small cell lung cancer treated with radiotherapy and immunotherapy
Translational Lung Cancer Research
2026;
15
(4)
:82
.
(30 April 2026)
Air pollution, driver mutations, and survival in non-small cell lung cancer: insights from a high-altitude Hispanic cohort
Translational Lung Cancer Research
2026;
15
(4)
:83
.
(30 April 2026)
TROP2 expression as a prognostic predictor for osimertinib in patients with EGFR-mutant non-small cell lung cancer
Translational Lung Cancer Research
2026;
15
(4)
:84
.
(30 April 2026)
Occupational physical workload and risk of lung cancer and chronic respiratory diseases: a prospective cohort study of the UK Biobank
Translational Lung Cancer Research
2026;
15
(4)
:85
.
(30 April 2026)
Accelerating tumor evolution and enhancing immunotherapy efficacy in lung adenocarcinoma based on EXO1 inhibition
Translational Lung Cancer Research
2026;
15
(4)
:86
.
(30 April 2026)
“Variant matters”: the impact of ALK fusion subtypes on progression and response in non-small-cell lung cancer—data from clinical practice from Polish centers
Translational Lung Cancer Research
2026;
15
(4)
:87
.
(30 April 2026)
Association between patient-reported outcomes and pathological response in neoadjuvant chemoimmunotherapy—a post hoc analysis of the TD-FOREKNOW trial
Translational Lung Cancer Research
2026;
15
(4)
:88
.
(30 April 2026)
Evaluating the early therapeutic response of radiofrequency ablation in rabbit VX2 lung tumors: a comparison of four diffusion weighted imaging models
Translational Lung Cancer Research
2026;
15
(4)
:89
.
(30 April 2026)
Novel lipid metabolism-related gene signature associated with clinical and immune features in lung adenocarcinoma patients experiencing lymph node metastasis
Translational Lung Cancer Research
2026;
15
(4)
:90
.
(30 April 2026)
Assessing current diagnostic, staging, and treatment practices in community and academic centers for individuals with stage IB–IIIA non-small cell lung cancer
Translational Lung Cancer Research
2026;
15
(4)
:91
.
(30 April 2026)
The IASLC grading system as a predictor for EGFR-TKI therapy in patients with EGFR-mutant lung adenocarcinoma
Translational Lung Cancer Research
2026;
15
(4)
:92
.
(30 April 2026)
Beyond miRNAs: exploratory profiling of PIWI-interacting RNAs and small nucleolar RNAs in non-small cell lung cancer-related malignant pleural effusions
Translational Lung Cancer Research
2026;
15
(4)
:93
.
(30 April 2026)
Pre-clinical efficacy of trastuzumab deruxtecan plus sotorasib in KRASG12C-mutant non-small cell lung cancer and exploratory HER2 profiling in human tumors
Translational Lung Cancer Research
2026;
15
(4)
:94
.
(30 April 2026)
Timing of definitive pleural intervention within systemic anticancer therapy in malignant pleural effusion from high-response lung cancers: a retrospective single-center cohort study
Translational Lung Cancer Research
2026;
15
(4)
:95
.
(30 April 2026)
Consolidative thoracic radiotherapy after first-line chemoimmunotherapy in extensive-stage small-cell lung cancer: a multicenter retrospective study
Translational Lung Cancer Research
2026;
15
(4)
:96
.
(30 April 2026)
Real-world effectiveness and safety of adebrelimab as first-line treatment in patients with extensive-stage small cell lung cancer
Translational Lung Cancer Research
2026;
15
(4)
:97
.
(30 April 2026)
Identification of prognostic biomarkers and immunotherapy response predictors in lung adenocarcinoma: integrative Mendelian randomization and machine learning analysis
Translational Lung Cancer Research
2026;
15
(4)
:98
.
(30 April 2026)
Cadonilimab induction and consolidation for unresectable stage III non-small cell lung cancer patients receiving concurrent chemoradiation: safety run-in results of a prospective, phase II trial
Translational Lung Cancer Research
2026;
15
(4)
:99
.
(30 April 2026)
Gender disparities in the overall survival of patients with minimally invasive squamous cell carcinoma of the lung: a retrospective analysis of the Surveillance, Epidemiology, and End Results Program database
Translational Lung Cancer Research
2026;
15
(4)
:100
.
(30 April 2026)
Review Article
The resistance landscape of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer: molecular mechanisms and novel therapeutic strategies
Translational Lung Cancer Research
2026;
15
(4)
:101
.
(30 April 2026)
Understanding the dual role of granulocyte-macrophage colony-stimulating factor in the lung cancer tumor microenvironment and its therapeutic implications
Translational Lung Cancer Research
2026;
15
(4)
:102
.
(30 April 2026)
From biology to the clinic: research evidence and therapeutic advances of TROP2-targeted antibody-drug conjugates in small cell lung cancer
Translational Lung Cancer Research
2026;
15
(4)
:103
.
(30 April 2026)
Pulmonary ground glass opacity tumor: a curable subtype of lung cancer when treated within the “surgical curative time window”
Translational Lung Cancer Research
2026;
15
(4)
:104
.
(30 April 2026)
Methylated circulating tumor DNA: technical challenges and clinical applications in non-small cell lung cancer patients—a narrative review
Translational Lung Cancer Research
2026;
15
(4)
:105
.
(30 April 2026)
Targeted therapy for stage IA non-small cell lung cancer with EGFR mutations: a scoping review
Translational Lung Cancer Research
2026;
15
(4)
:106
.
(30 April 2026)
Lung cancer associated with cystic airspaces in the perioperative immunotherapy era: radiologic and pathologic pitfalls, surgical extent, and management implications
Translational Lung Cancer Research
2026;
15
(4)
:107
.
(30 April 2026)
Narrative review of the similarities and differences between immune checkpoint inhibitor- and antibody-drug conjugate-associated pneumonitis
Translational Lung Cancer Research
2026;
15
(4)
:108
.
(30 April 2026)
Case Report
A lung squamous cell carcinoma demonstrating spontaneous partial regression of the primary tumor with lymph node metastasis: a case report with analysis of the tumor immune microenvironment
Translational Lung Cancer Research
2026;
15
(4)
:109
.
(30 April 2026)
Prolonged complete metabolic response to chemotherapy combined with amivantamab with high grade cutaneous toxicity after osimertinib resistance in an uncommon T751_I759delinsAsp EGFR-mutant lung adenocarcinoma: a case report
Translational Lung Cancer Research
2026;
15
(4)
:110
.
(30 April 2026)
Clonal relationship in a rare pulmonary mixed tumor: shared ALK fusion in atypical carcinoid and adenocarcinoma—a case report
Translational Lung Cancer Research
2026;
15
(4)
:111
.
(30 April 2026)
Two-year treatment-free sustained remission after chemo-immunotherapy in a 52-year-old male with recurrent ARID1A-mutant lung adenocarcinoma: a case report
Translational Lung Cancer Research
2026;
15
(4)
:112
.
(30 April 2026)
ALK-tyrosine kinase inhibitor resistance due to acquired MET amplification in ALK-fusion positive advanced NSCLC effectively treated by lorlatinib-vebreltinib combination: a case report and literature review
Translational Lung Cancer Research
2026;
15
(4)
:113
.
(30 April 2026)
Editorial Commentary
Precision medicine in the first-line treatment of EGFR-mutated non-small cell lung cancer: moving beyond “one-size-fits-all”
Translational Lung Cancer Research
2026;
15
(4)
:114
.
(30 April 2026)
Survival, toxicity, and sequencing: navigating the new first-line standard established by FLAURA2
Translational Lung Cancer Research
2026;
15
(4)
:115
.
(30 April 2026)
